Lisata Therapeutics annual revenue
2010
2011
2012
2013
2014
2015
2016
2022
2023
2024
2025
Lisata Therapeutics Revenue Growth & History (LSTA)
Lisata Therapeutics reported $170,000 in revenue for fiscal 2025, a decrease of 83.00% from the previous fiscal year.
View full Lisata Therapeutics company overviewLisata Therapeutics annual revenue and growth
| Fiscal year | Period ended | Revenue | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $170,000 | −$830,000 | −83.00% |
| 2024 | 2024-12-31 | $1.0M | $1.0M | — |
| 2023 | 2023-12-31 | $0 | $0 | — |
| 2022 | 2022-12-31 | $0 | — | — |
| 2016 | 2016-12-31 | $35.3M | $12.8M | +56.90% |
| 2015 | 2015-12-31 | $22.5M | $4.5M | +25.36% |
| 2014 | 2014-12-31 | $17.9M | $3.3M | +22.30% |
| 2013 | 2013-12-31 | $14.7M | $338,566 | +2.36% |
| 2012 | 2012-12-31 | $14.3M | $4.3M | +42.58% |
| 2011 | 2011-12-31 | $10.1M | −$59.8M | −85.61% |
| 2010 | 2010-12-31 | $69.8M | — | — |
Lisata Therapeutics quarterly revenue
Q2.10
Q3.10
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q3.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Revenue | Change | YoY growth |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $0 | −$70,000 | −100.00% |
| Q1 2026 | 2026-03-31 | $0 | $0 | — |
| Q4 2025 | 2025-12-31 | $100,000 | −$900,000 | −90.00% |
| Q3 2025 | 2025-09-30 | $0 | $0 | — |
| Q2 2025 | 2025-06-30 | $70,000 | $70,000 | — |
| Q1 2025 | 2025-03-31 | $0 | $0 | — |
| Q4 2024 | 2024-12-31 | $1.0M | $1.0M | — |
| Q3 2024 | 2024-09-30 | $0 | $0 | — |
| Q2 2024 | 2024-06-30 | $0 | $0 | — |
| Q1 2024 | 2024-03-31 | $0 | $0 | — |
| Q4 2023 | 2023-12-31 | $0 | — | — |
| Q3 2023 | 2023-09-30 | $0 | $0 | — |
| Q2 2023 | 2023-06-30 | $0 | — | — |
| Q1 2023 | 2023-03-31 | $0 | — | — |
| Q3 2022 | 2022-09-30 | $0 | — | — |
| Q1 2017 | 2017-03-31 | $7.9M | $433,188 | +5.78% |
| Q4 2016 | 2016-12-31 | $10.2M | $2.6M | +34.61% |
| Q3 2016 | 2016-09-30 | $9.3M | $3.4M | +58.23% |
| Q2 2016 | 2016-06-30 | $8.3M | $2.4M | +41.48% |
| Q1 2016 | 2016-03-31 | $7.5M | $4.3M | +136.09% |
| Q4 2015 | 2015-12-31 | $7.6M | $2.3M | +43.29% |
| Q3 2015 | 2015-09-30 | $5.9M | $1.8M | +42.99% |
| Q2 2015 | 2015-06-30 | $5.9M | $1.4M | +30.70% |
| Q1 2015 | 2015-03-31 | $3.2M | −$883,721 | −21.79% |
| Q4 2014 | 2014-12-31 | $5.3M | $1.2M | +29.38% |
| Q3 2014 | 2014-09-30 | $4.1M | $411,000 | +11.09% |
| Q2 2014 | 2014-06-30 | $4.5M | $130,000 | +2.98% |
| Q1 2014 | 2014-03-31 | $4.1M | $1.5M | +60.70% |
| Q4 2013 | 2013-12-31 | $4.1M | $1.3M | +48.23% |
| Q3 2013 | 2013-09-30 | $3.7M | −$726,961 | −16.40% |
| Q2 2013 | 2013-06-30 | $4.4M | $986,903 | +29.27% |
| Q1 2013 | 2013-03-31 | $2.5M | −$1.2M | −33.10% |
| Q4 2012 | 2012-12-31 | $2.8M | $16.7M | +119.75% |
| Q3 2012 | 2012-09-30 | $4.4M | $2.3M | +103.67% |
| Q2 2012 | 2012-06-30 | $3.4M | $1.2M | +52.53% |
| Q1 2012 | 2012-03-31 | $3.8M | −$15.8M | −80.74% |
| Q4 2011 | 2011-12-31 | −$13.9M | — | — |
| Q3 2011 | 2011-09-30 | $2.2M | −$14.3M | −86.79% |
| Q2 2011 | 2011-06-30 | $2.2M | −$17.2M | −88.61% |
| Q1 2011 | 2011-03-31 | $19.6M | — | — |
| Q3 2010 | 2010-09-30 | $16.5M | — | — |
| Q2 2010 | 2010-06-30 | $19.4M | — | — |
Lisata Therapeutics revenue growth trends
Lisata Therapeutics's latest reported quarter, Q2 2026, generated $0 in revenue, a decrease of 100.00% year over year.
About the data
What revenue means
Revenue is the top-line amount a company reports from selling goods and services before expenses are deducted. Fiscal periods can differ from calendar years, so each table includes the exact period end date.
Financial data
Standardized company financials
TickerStat standardizes company financial facts for consistent comparison. Derived growth rates use the displayed values and are not guidance or forecasts.
Review Lisata Therapeutics source filings ↗Community posts
Lisata acquires Marea and signs $225 million financing agreement
Lisata ($LSTA) Therapeutics acquired Marea Therapeutics in a stock-for-stock transaction and signed a concurrent agreement for approximately $225 million in gross private-placement proceeds. The financing involves non-voting convertible pre ...
